SCHEDULE 13G/A: Frazier Funds and Affiliates Update Passive Stake in AnaptysBio, Inc. with Amended SEC Filing

Frazier Life Sciences and Healthcare funds, along with associated individuals, have filed an amended Schedule 13G/A to update their beneficial ownership of AnaptysBio, Inc. Common Stock.

Summary

• Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences Public Overage Fund, L.P., Frazier Life Sciences X, L.P., Frazier Life Sciences XI, L.P., Frazier Healthcare VII, L.P., Frazier Healthcare VII-A, L.P., and their respective general partners and managing members, along with several individuals, have jointly filed an Amendment No. 2 to Schedule 13G.
• The filing reports beneficial ownership of AnaptysBio, Inc. Common Stock as of January 31, 2025.
• The percentages of ownership are calculated based on 30,428,682 shares of Common Stock outstanding as of October 31, 2024, as reported in AnaptysBio, Inc.'s Form 10-Q filed on November 5, 2024.
• Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., and FHMLSP, L.L.C. each beneficially own 148,844 shares, representing 0.5% of the class.
• Frazier Life Sciences Public Overage Fund, L.P., FHMLSP Overage, L.P., and FHMLSP Overage, L.L.C. each beneficially own 18,902 shares, representing 0.1% of the class.
• Frazier Life Sciences X, L.P., FHMLS X, L.P., and FHMLS X, L.L.C. each beneficially own 18,715 shares, representing 0.1% of the class.
• Frazier Life Sciences XI, L.P., FHMLS XI, L.P., and FHMLS XI, L.L.C. each beneficially own 40,222 shares, representing 0.1% of the class.
• Frazier Healthcare VII, L.P. beneficially owns 121,206 shares (0.4%), and Frazier Healthcare VII-A, L.P. beneficially owns 34,540 shares (0.1%).
• FHM VII, L.P. and FHM VII, L.L.C. each beneficially own an aggregate of 155,746 shares, representing 0.5% of the class, combining holdings from Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P.
• Among the individuals, James N. Topper reports the highest aggregate beneficial ownership with 463,241 shares (1.5%), including 80,812 sole voting/dispositive power and 382,429 shared voting/dispositive power.
• Patrick J. Heron reports 391,539 shares (1.3%), including 9,110 sole voting/dispositive power and 382,429 shared voting/dispositive power.
• Albert Cha and James Brush each report 167,746 shares (0.6%) with shared voting/dispositive power.
• Alan Frazier, Nader Naini, Nathan Every, and Brian Morfitt each report beneficial ownership of shares through their association with the Frazier Healthcare VII entities, with Nathan Every holding 160,369 shares (0.5%) and Brian Morfitt holding 161,115 shares (0.5%) including direct holdings.
• Daniel Estes reports 40,222 shares (0.1%) with shared voting/dispositive power.
• The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of AnaptysBio, Inc.

Sentiment

Score: 5

Explanation: The document is a factual, compliance-driven filing (Schedule 13G/A) reporting beneficial ownership. It contains no positive or negative operational or financial news, thus a neutral sentiment score is appropriate.

Future Outlook

This Schedule 13G/A filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Industry Context

This filing is a routine disclosure of beneficial ownership by a group of investment funds and individuals in a biotechnology company. It reflects a passive investment stake and does not provide broader insights into industry trends or competitive dynamics beyond the fact that these funds continue to hold a position in AnaptysBio, Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding the beneficial ownership structure of a significant group of investors, confirming their passive stake in the company.

Key Dates

Keywords

AnaptysBio Inc., SEC Filing, Schedule 13G/A, Beneficial Ownership, Frazier Life Sciences, Frazier Healthcare, Common Stock, Institutional Investor, Passive Investment, Biotechnology